Home > OJNeph>

Dr. Konstantinos Tziomalos

Aristotle University of Thessaloniki, AHEPA Hospital, Greece.


Email: ktziomalos@yahoo.com



2007  Ph.D., Aristotle University of Thessaloniki, Greece.

2003  M.Sc., Aristotle University of Thessaloniki, Greece.

1998  B.Sc., Aristotle University of Thessaloniki, Greece.



  1. Koiou E, Tziomalos K, Katsikis I, Kandaraki EA, Kalaitzakis E, Delkos D, Vosnakis C, Panidis D. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecol Endocrinol 2011 Jul 14.
  2. Athyros VG, Karagiannis A, Ganotakis E, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Elisaf MS, Mikhailidis DP; for the Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-1668.
  3. Pagourelias ED, Gossios TD, Tziomalos KKaragiannis A, Geleris P, Athyros VGResidual cardiac risk reduction beyond lipid lowering. Hellenic J Cardiol 2011; 52: 197-203.
  4. Koiou E, Dinas K, Tziomalos K, Toulis K, Kandaraki EA, Kalaitzakis E, Katsikis I, Panidis D. The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria. Obes Facts 2011; 4: 145-150.
  5. Katsinelos P, Tziomalos K, Fasoulas K, Paroutoglou G, Koufokotsios A, Mimidis K, Terzoudis S, Maris T, Beltsis A, Geros C, Chatzimavroudis G. Can capsule endoscopy be used as a diagnostic tool in the evaluation of non-bleeding indications in daily clinical practice? A prospective study. Medical Principles and Practice 2011; 20: 362-367.
  6. Koiou E, Tziomalos K, Katsikis I, Kalaitzakis E, Kandaraki EA, Tsourdi EA, Delkos D, Papadakis E, Panidis D. Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels. Eur J Endocrinol 2011; 165: 63-68.
  7. Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing The Treatment Effect in Metabolic Syndrome without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. Curr Vasc Pharmacol 2011 Apr 11.
  8. Athyros VGTziomalos K, Daskalopoulos GNKaragiannis AMikhailidis DP. Statin-based treatment for cardiovascular risk and non alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-171.
  9. Athyros VGKaragiannis ATziomalos K, Gossios TD, Mikhailidis DP. Raised liver enzymes in patients taking statins. Lancet 2011; 377: 1075-1076.
  10. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011; 5: 24-34.
  11. Tziomalos KAthyros VGKaragiannis AMikhailidis DP. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc Med J 2011; 5: 85-89.
  12. Tsantilas D, Hatzitolios AI, Tziomalos K, Karamitsos D, Papadimitriou D. The effects of buflomedil on skin blood flow in patients with type 2 diabetes mellitus without overt micro- or macroangiopathy. Int Angiol 2011; 30: 164-171. 
  13. Athyros VGTziomalos KKaragiannis AMikhailidis DP. Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev 2011; 12: 515-524.
  14. Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, Delkos D, Kandaraki EA, Panidis D. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J 2011; 58: 237-246.
  15. Panidis D, Tziomalos K, Koiou E, Kandaraki EA, Tsourdi E, Delkos D, Kalaitzakis E, Katsikis I. The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study. Reprod Biol Endocrinol 2010; 8: 151.
  16. Stavrinou E, Koumaras C, Gossios TD, Tziomalos KAthyros VGKaragiannis AAtherosclerotic renal artery stenosis: an update on diagnosis and management. Curr Vasc Pharmacol 2010 Dec 14. [Epub ahead of print].
  17. Athyros VGTziomalos KKaragiannis AMikhailidis DP. Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes? Curr Pharm Des 2010; 16: 3839-3847.
  18. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP; for the GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922.
  19. Athyros VGTziomalos KKaragiannis AMikhailidis DP. To switch (statins) or not to switch? That is the question. Expert Opin Pharmacother 2010; 11: 2943-2946.
  20. Athyros VGTziomalos KKaragiannis A, Mikhailidis DP. Statin-fibrate combination for mixed dyslipidaemia: a limited option? Curr Med Res Opin 2010; 26: 2137-2140.